+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anxiety Drugs Market - Global Forecast 2026-2032- Product Image
Anxiety Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Anxiety Drugs Market - Global Forecast 2026-2032

  • Report

  • 191 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5337779
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Anxiety Drugs Market is projected to reach USD 17.73 Billion in 2026. It is expected to continue growing at a CAGR of 9.16%, reaching USD 30.11 Billion by 2032.

Anxiety drugs remain a core segment of the global mental health therapeutics landscape as anxiety disorders affect an estimated 301 million people worldwide, according to the World Health Organization. Demand is supported by high disease burden, broader screening in primary care, expanding mental health awareness, and sustained use of pharmacologic therapies such as selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, benzodiazepines, buspirone, beta blockers, and adjunctive agents.

Clinical practice continues to favor SSRIs and SNRIs as first-line long-term treatment options for generalized anxiety disorder, panic disorder, social anxiety disorder, and related conditions, while benzodiazepines are increasingly reserved for short-term or carefully monitored use because of dependence, sedation, withdrawal, and misuse risks. This balance is shaping product positioning, prescribing behavior, payer review, pharmacovigilance priorities, and lifecycle strategies across branded and generic anxiety medications.

Transformative Shifts in the Anxiety Treatment Landscape

The anxiety drugs landscape is shifting from symptom suppression toward safer, more personalized, and integrated care. Prescribers are emphasizing long-term tolerability, lower abuse potential, faster onset, reduced sexual dysfunction, fewer drug-drug interactions, and compatibility with psychotherapy and digital mental health interventions. These priorities are influencing development pipelines and commercial strategies in both established and emerging markets.

Regulatory scrutiny around controlled substances, especially benzodiazepines, is also changing utilization patterns through tighter monitoring, prescribing limits, and patient-risk evaluation. At the same time, the post-pandemic rise in anxiety symptoms has increased demand for accessible treatment, creating opportunities for telepsychiatry-enabled prescribing, pharmacy-led adherence support, measurement-based care, and evidence-based digital therapeutics that complement medication management.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across anxiety drug discovery, clinical development, safety surveillance, and patient support. In research, AI-enabled target identification, molecular modeling, literature mining, and biomarker analysis are helping teams screen compounds more efficiently and explore novel mechanisms beyond traditional monoamine pathways.

In commercial and clinical operations, AI is improving patient stratification, adverse-event monitoring, adherence prediction, signal detection, and real-world evidence generation. Large language model-enabled clinical documentation, AI triage, and remote monitoring may reduce care bottlenecks and support earlier intervention, but industry leaders must address bias, data privacy, explainability, clinical validation, and regulatory oversight before AI can be trusted at scale in psychiatric drug decision-making.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East & Africa

North America remains a leading region for anxiety drugs due to high diagnosis rates, broad insurance coverage, established psychiatric and primary care prescribing pathways, and strong generic penetration. The United States is especially important because anxiety disorders are among the most common mental health conditions, supported by national surveillance and treatment guidelines, while Canada’s public health focus on mental wellness supports access initiatives, cautious prescribing, and guideline-based medication use.

Europe benefits from mature healthcare systems, strong pharmacovigilance standards, and clear prescribing controls, particularly across the European Union, where evidence-based assessment, reimbursement review, and controlled-substance oversight influence adoption. Asia-Pacific is expanding as China, India, Japan, South Korea, Australia, and ASEAN economies invest in mental health awareness, telemedicine, primary care integration, and broader access to psychiatric care. Latin America is gaining momentum through Brazil and Mexico, where retail pharmacy channels, private healthcare expansion, and generic availability support use, although affordability and specialist availability remain constraints. The Middle East and Africa show rising recognition of anxiety disorders, with GCC countries moving faster due to healthcare modernization, digital health investment, and specialist service expansion, while many African markets still face infrastructure gaps, medicine availability challenges, and stigma-related barriers.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7 & NATO

Within ASEAN, improving mental health literacy, expanding private healthcare networks, and wider telehealth adoption are increasing demand for affordable generics and digitally supported anxiety care. The GCC is investing heavily in healthcare transformation, digital health, specialist services, and national mental health programs, creating opportunities for premium therapies, hospital partnerships, and localized patient-support models.

The European Union is shaped by harmonized safety standards, health technology assessment discipline, pricing pressure, pharmacovigilance requirements, and a strong preference for evidence-based prescribing. BRICS markets provide scale and long-term volume potential, especially in China, India, and Brazil, but require pricing discipline, local regulatory expertise, and strategies suited to diverse reimbursement and access conditions. G7 countries continue to drive innovation, clinical standards, guideline development, and reimbursement expectations. NATO member markets overlap significantly with high-income healthcare systems, where supply resilience, controlled-substance monitoring, medicine security, and mental health workforce capacity are strategic priorities.

Key Country Insights Across Major Anxiety Drug Markets

The United States leads anxiety drug utilization through high awareness, extensive primary care prescribing, telepsychiatry adoption, and strong demand for SSRIs, SNRIs, and carefully monitored short-term anxiolytics. Canada emphasizes public health access, mental wellness initiatives, and cautious prescribing, while Mexico and Brazil offer growth through expanding private care, retail pharmacy channels, urban mental health services, and demand for cost-effective generics.

In Europe, the United Kingdom, Germany, France, Italy, and Spain show mature use of antidepressant-based anxiety treatment, supported by clinical guidelines, reimbursement frameworks, and pharmacovigilance systems. Russia remains a distinct market with local regulatory, access, and prescribing dynamics. China and India represent high-volume opportunities as mental health services expand, stigma gradually declines, and digital health channels improve reach, while Japan and South Korea emphasize quality, safety, aging-population considerations, and careful medication management. Australia combines strong mental health awareness with integrated primary care, public mental health initiatives, and telehealth adoption, supporting structured access to pharmacologic and behavioral treatment options.

Actionable Recommendations for Anxiety Drug Industry Leaders

Industry leaders should prioritize differentiated anxiety therapies with faster onset, durable efficacy, strong tolerability, fewer discontinuation challenges, and lower dependence risk. Development strategies should also address real-world patient needs such as comorbid depression, insomnia, substance-use risk, chronic disease, and treatment adherence. Companies should strengthen real-world evidence programs that demonstrate adherence, relapse reduction, functional improvement, health-resource impact, and safety in diverse populations.

Commercial teams should align portfolio strategy with regional access realities by pairing branded innovation with high-quality generics where appropriate. Partnerships with telehealth providers, behavioral health networks, pharmacy systems, and AI-enabled adherence tools can improve patient engagement and continuity of care, while controlled-substance compliance, pharmacovigilance, transparent patient education, and responsible promotion should remain central to risk management.

Research Methodology

This executive summary is developed using a secondary-research-led methodology that synthesizes publicly available and authoritative sources, including the World Health Organization, national health agencies, regulatory guidance, peer-reviewed clinical literature, prescribing guidelines, pharmacovigilance resources, and market access observations across major regions.

The analysis emphasizes verified disease-burden indicators, treatment standards, regulatory direction, digital health adoption, medication safety considerations, and competitive dynamics without relying on market estimation, market sizing, market share, or market forecasting. Insights are cross-checked for consistency across clinical, commercial, and policy sources to support practical interpretation for pharmaceutical manufacturers, investors, healthcare providers, and market strategy teams.

Conclusion: Strategic Outlook for Anxiety Drugs

The anxiety drugs market is evolving as unmet need, post-pandemic mental health demand, safety expectations, and digital care models reshape treatment pathways. Established drug classes will continue to anchor therapy, but competitive advantage is moving toward safer mechanisms, better patient selection, stronger adherence support, and integrated medication management.

Organizations that combine clinical differentiation, regional access discipline, AI-enabled evidence generation, and responsible prescribing frameworks will be best positioned to build durable relevance. The next phase of the anxiety drugs landscape will reward strategies that address both symptom relief and long-term patient functioning while meeting rising expectations for safety, access, and evidence-based care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Anxiety Drugs Market, by Drug Class
7.1. Introduction
7.2. Benzodiazepine
7.2.1. Alprazolam
7.2.2. Clonazepam
7.2.3. Diazepam
7.2.4. Lorazepam
7.3. Beta Blocker
7.4. Buspirone
7.5. Selective Serotonin Reuptake Inhibitor
7.5.1. Escitalopram
7.5.2. Fluoxetine
7.5.3. Paroxetine
7.5.4. Sertraline
7.6. Serotonin Norepinephrine Reuptake Inhibitor
7.6.1. Duloxetine
7.6.2. Venlafaxine
8. Anxiety Drugs Market, by Route Of Administration
8.1. Introduction
8.2. Injection
8.2.1. Intramuscular
8.2.2. Intravenous
8.3. Nasal Spray
8.4. Oral
8.4.1. Capsule
8.4.2. Liquid
8.4.3. Tablet
8.5. Transdermal
9. Anxiety Drugs Market, by Patient Type
9.1. Introduction
9.2. Adult
9.3. Geriatric
9.4. Pediatric
10. Anxiety Drugs Market, by Indication
10.1. Introduction
10.2. Generalized Anxiety Disorder (GAD)
10.3. Obsessive-Compulsive Disorder (OCD)
10.4. Panic Disorder
10.5. Post-Traumatic Stress Disorder (PTSD)
10.6. Social Anxiety Disorder (SAD)
11. Anxiety Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Anxiety Drugs Market, by Region
12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East
13. Anxiety Drugs Market, by Group
13.1. NATO
13.2. G7
13.3. BRICS
13.4. European Union
13.5. ASEAN
13.6. GCC
14. Anxiety Drugs Market, by Country
14.1. China
14.2. United States
14.3. Japan
14.4. India
14.5. Germany
14.6. United Kingdom
14.7. Australia
14.8. France
14.9. South Korea
14.10. Italy
14.11. Canada
14.12. Russia
14.13. Brazil
14.14. Mexico
14.15. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AbbVie Inc.
16.2. Addex Therapeutics Ltd.
16.3. Amorsa Therapeutics Inc.
16.4. Apotex Inc.
16.5. AstraZeneca PLC
16.6. Avineuro Pharmaceuticals, Inc.
16.7. Azevan Pharmaceuticals, Inc.
16.8. Bausch Health Companies Inc.
16.9. Bionomics Limited
16.10. Chengdu Kanghong Pharmaceutical Group Co., Ltd.
16.11. Eli Lilly and Company
16.12. F. Hoffmann-La Roche Ltd.
16.13. GlaxoSmithKline PLC
16.14. H. Lundbeck A/S
16.15. Huahai Pharmaceutical Co. Ltd.
16.16. Intra-Cellular Therapies Inc.
16.17. Johnson & Johnson Services Inc.
16.18. Merck & Co., Inc.
16.19. Novartis AG
16.20. Olainfarm
16.21. Otsuka Pharmaceutical Co., Ltd.
16.22. Pfizer Inc.
16.23. Sanofi S.A.
16.24. Sun Pharmaceutical Industries Limited
16.25. Swisschem Healthcare
16.26. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL ANXIETY DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ANXIETY DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ANXIETY DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ANXIETY DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ANXIETY DRUGS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ANXIETY DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ANXIETY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ANXIETY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ANXIETY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ANXIETY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ANXIETY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ANXIETY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL ANXIETY DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL ANXIETY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ANXIETY DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL BENZODIAZEPINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL BENZODIAZEPINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL BENZODIAZEPINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL ALPRAZOLAM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL ALPRAZOLAM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL ALPRAZOLAM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL CLONAZEPAM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL CLONAZEPAM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL CLONAZEPAM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL DIAZEPAM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL DIAZEPAM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL DIAZEPAM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL LORAZEPAM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL LORAZEPAM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL LORAZEPAM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL BETA BLOCKER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL BETA BLOCKER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL BETA BLOCKER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL BUSPIRONE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL BUSPIRONE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL BUSPIRONE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITOR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITOR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITOR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL ESCITALOPRAM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL ESCITALOPRAM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL ESCITALOPRAM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL FLUOXETINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL FLUOXETINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL FLUOXETINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL PAROXETINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL PAROXETINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL PAROXETINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL SERTRALINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL SERTRALINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL SERTRALINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL DULOXETINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL DULOXETINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL DULOXETINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL VENLAFAXINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL VENLAFAXINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL VENLAFAXINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL INJECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL INJECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL INJECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL NASAL SPRAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL NASAL SPRAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL NASAL SPRAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL CAPSULE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL CAPSULE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL CAPSULE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL LIQUID MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL LIQUID MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL LIQUID MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL TABLET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL TABLET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL TABLET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL GENERALIZED ANXIETY DISORDER (GAD) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL GENERALIZED ANXIETY DISORDER (GAD) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL GENERALIZED ANXIETY DISORDER (GAD) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL OBSESSIVE-COMPULSIVE DISORDER (OCD) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL OBSESSIVE-COMPULSIVE DISORDER (OCD) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL OBSESSIVE-COMPULSIVE DISORDER (OCD) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL PANIC DISORDER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL PANIC DISORDER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL PANIC DISORDER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL POST-TRAUMATIC STRESS DISORDER (PTSD) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL SOCIAL ANXIETY DISORDER (SAD) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL SOCIAL ANXIETY DISORDER (SAD) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL SOCIAL ANXIETY DISORDER (SAD) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL ANXIETY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC ANXIETY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2017-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC ANXIETY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 125. EUROPE ANXIETY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. EUROPE ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 127. EUROPE ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2017-2032 (USD MILLION)
TABLE 128. EUROPE ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 129. EUROPE ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 130. EUROPE ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 131. EUROPE ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 132. EUROPE ANXIETY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 133. EUROPE ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 134. EUROPE ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 135. EUROPE ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 136. NORTH AMERICA ANXIETY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 137. NORTH AMERICA ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 138. NORTH AMERICA ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2017-2032 (USD MILLION)
TABLE 139. NORTH AMERICA ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 140. NORTH AMERICA ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 141. NORTH AMERICA ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 142. NORTH AMERICA ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 143. NORTH AMERICA ANXIETY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 144. NORTH AMERICA ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 145. NORTH AMERICA ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 146. NORTH AMERICA ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 147. LATIN AMERICA ANXIETY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 148. LATIN AMERICA ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 149. LATIN AMERICA ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2017-2032 (USD MILLION)
TABLE 150. LATIN AMERICA ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 151. LATIN AMERICA ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 152. LATIN AMERICA ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 153. LATIN AMERICA ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 154. LATIN AMERICA ANXIETY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 155. LATIN AMERICA ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 156. LATIN AMERICA ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 157. LATIN AMERICA ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 158. AFRICA ANXIETY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 159. AFRICA ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 160. AFRICA ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2017-2032 (USD MILLION)
TABLE 161. AFRICA ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 162. AFRICA ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 163. AFRICA ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 164. AFRICA ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 165. AFRICA ANXIETY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 166. AFRICA ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 167. AFRICA ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 168. AFRICA ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 169. MIDDLE EAST ANXIETY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 170. MIDDLE EAST ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 171. MIDDLE EAST ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2017-2032 (USD MILLION)
TABLE 172. MIDDLE EAST ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 173. MIDDLE EAST ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 174. MIDDLE EAST ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 175. MIDDLE EAST ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 176. MIDDLE EAST ANXIETY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 177. MIDDLE EAST ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 178. MIDDLE EAST ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 179. MIDDLE EAST ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 180. GLOBAL ANXIETY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 181. NATO ANXIETY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 182. NATO ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 183. NATO ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2017-2032 (USD MILLION)
TABLE 184. NATO ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 185. NATO ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 186. NATO ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 187. NATO ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 188. NATO ANXIETY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 189. NATO ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 190. NATO ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 191. NATO ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 192. G7 ANXIETY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 193. G7 ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 194. G7 ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2017-2032 (USD MILLION)
TABLE 195. G7 ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 196. G7 ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 197. G7 ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 198. G7 ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 199. G7 ANXIETY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 200. G7 ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 201. G7 ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 202. G7 ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 203. BRICS ANXIETY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 204. BRICS ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 205. BRICS ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2017-2032 (USD MILLION)
TABLE 206. BRICS ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 207. BRICS ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 208. BRICS ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 209. BRICS ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 210. BRICS ANXIETY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 211. BRICS ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 212. BRICS ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 213. BRICS ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 214. EUROPEAN UNION ANXIETY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 216. EUROPEAN UNION ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2017-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 220. EUROPEAN UNION ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION ANXIETY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 222. EUROPEAN UNION ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 223. EUROPEAN UNION ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 224. EUROPEAN UNION ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 225. ASEAN ANXIETY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 226. ASEAN ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 227. ASEAN ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2017-2032 (USD MILLION)
TABLE 228. ASEAN ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 229. ASEAN ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 230. ASEAN ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 231. ASEAN ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 232. ASEAN ANXIETY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 233. ASEAN ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 234. ASEAN ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 235. ASEAN ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 236. GCC ANXIETY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 237. GCC ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 238. GCC ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2017-2032 (USD MILLION)
TABLE 239. GCC ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 240. GCC ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 241. GCC ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 242. GCC ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 243. GCC ANXIETY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 244. GCC ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 245. GCC ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 246. GCC ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 247. GLOBAL ANXIETY DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 248. CHINA ANXIETY DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 249. CHINA ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 250. CHINA ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2017-2032 (USD MILLION)
TABLE 251. CHINA ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 252. CHINA ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 253. CHINA ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 254. CHINA ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 255. CHINA ANXIETY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 256. CHINA ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 257. CHINA ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 258. CHINA ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 259. UNITED STATES ANXIETY DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 260. UNITED STATES ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 261. UNITED STATES ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2017-2032 (USD MILLION)
TABLE 262. UNITED STATES ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 263. UNITED STATES ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 264. UNITED STATES ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 265. UNITED STATES ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 266. UNITED STATES ANXIETY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 267. UNITED STATES ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 268. UNITED STATES ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 269. UNITED STATES ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 270. JAPAN ANXIETY DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 271. JAPAN ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 272. JAPAN ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2017-2032 (USD MILLION)
TABLE 273. JAPAN ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 274. JAPAN ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 275. JAPAN ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 276. JAPAN ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 277. JAPAN ANXIETY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 278. JAPAN ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 279. JAPAN ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 280. JAPAN ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 281. INDIA ANXIETY DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 282. INDIA ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 283. INDIA ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2017-2032 (USD MILLION)
TABLE 284. INDIA ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 285. INDIA ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 286. INDIA ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 287. INDIA ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 288. INDIA ANXIETY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 289. INDIA ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 290. INDIA ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 291. INDIA ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 292. GERMANY ANXIETY DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 293. GERMANY ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 294. GERMANY ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2017-2032 (USD MILLION)
TABLE 295. GERMANY ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 296. GERMANY ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 297. GERMANY ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 298. GERMANY ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 299. GERMANY ANXIETY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 300. GERMANY ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 301. GERMANY ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 302. GERMANY ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 303. UNITED KINGDOM ANXIETY DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 304. UNITED KINGDOM ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 305. UNITED KINGDOM ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2017-2032 (USD MILLION)
TABLE 306. UNITED KINGDOM ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 307. UNITED KINGDOM ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 308. UNITED KINGDOM ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 309. UNITED KINGDOM ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 310. UNITED KINGDOM ANXIETY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 311. UNITED KINGDOM ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 312. UNITED KINGDOM ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 313. UNITED KINGDOM ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 314. AUSTRALIA ANXIETY DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 315. AUSTRALIA ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 316. AUSTRALIA ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2017-2032 (USD MILLION)
TABLE 317. AUSTRALIA ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 318. AUSTRALIA ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 319. AUSTRALIA ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 320. AUSTRALIA ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 321. AUSTRALIA ANXIETY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 322. AUSTRALIA ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 323. AUSTRALIA ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 324. AUSTRALIA ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 325. FRANCE ANXIETY DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 326. FRANCE ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 327. FRANCE ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2017-2032 (USD MILLION)
TABLE 328. FRANCE ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 329. FRANCE ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 330. FRANCE ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 331. FRANCE ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 332. FRANCE ANXIETY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 333. FRANCE ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 334. FRANCE ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 335. FRANCE ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 336. SOUTH KOREA ANXIETY DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 337. SOUTH KOREA ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 338. SOUTH KOREA ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2017-2032 (USD MILLION)
TABLE 339. SOUTH KOREA ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 340. SOUTH KOREA ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 341. SOUTH KOREA ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 342. SOUTH KOREA ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 343. SOUTH KOREA ANXIETY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 344. SOUTH KOREA ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 345. SOUTH KOREA ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 346. SOUTH KOREA ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 347. ITALY ANXIETY DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 348. ITALY ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 349. ITALY ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2017-2032 (USD MILLION)
TABLE 350. ITALY ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 351. ITALY ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 352. ITALY ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 353. ITALY ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 354. ITALY ANXIETY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 355. ITALY ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 356. ITALY ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 357. ITALY ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 358. CANADA ANXIETY DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 359. CANADA ANXIETY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 360. CANADA ANXIETY DRUGS MARKET SIZE, BY BENZODIAZEPINE, 2017-2032 (USD MILLION)
TABLE 361. CANADA ANXIETY DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 362. CANADA ANXIETY DRUGS MARKET SIZE, BY SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITOR, 2017-2032 (USD MILLION)
TABLE 363. CANADA ANXIETY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 364. CANADA ANXIETY DRUGS MARKET SIZE, BY INJECTION, 2017-2032 (USD MILLION)
TABLE 365. CANADA ANXIETY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 366. CANADA ANXIETY DRUGS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 367. CANADA ANXIETY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 368. CANADA ANXIETY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 369. RUSSIA ANXIETY DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 370

Companies Mentioned

  • AbbVie Inc.
  • Addex Therapeutics Ltd.
  • Amorsa Therapeutics Inc.
  • Apotex Inc.
  • AstraZeneca PLC
  • Avineuro Pharmaceuticals, Inc.
  • Azevan Pharmaceuticals, Inc.
  • Bausch Health Companies Inc.
  • Bionomics Limited
  • Chengdu Kanghong Pharmaceutical Group Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Huahai Pharmaceutical Co. Ltd.
  • Intra-Cellular Therapies Inc.
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Olainfarm
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Limited
  • Swisschem Healthcare
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages191
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 17.73 Billion
Forecasted Market Value ( USD ) by 2032 $ 30.11 Billion
Compound Annual Growth Rate9.1%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Anxiolytics Market - Global Forecast 2026-2032 - Product Image

Anxiolytics Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From
Anxiolytics - Global Strategic Business Report - Product Image

Anxiolytics - Global Strategic Business Report

  • Report
  • 108 Pages
  • Global
From
Generalized Anxiety Disorder - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Generalized Anxiety Disorder - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 160 Pages
  • Global
From
Agoraphobia Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Agoraphobia Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 140 Pages
  • Global
From
Obsessive-Compulsive Disorder Drugs Market - Global Forecast 2026-2032 - Product Image

Obsessive-Compulsive Disorder Drugs Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From

About the Anxiety Drugs Market

The Anxiety Drugs market is a sector of the pharmaceutical industry that focuses on the development and sale of drugs used to treat anxiety disorders. Anxiety drugs are typically prescribed to treat a variety of conditions, including generalized anxiety disorder, panic disorder, social anxiety disorder, and post-traumatic stress disorder. Commonly prescribed anxiety drugs include benzodiazepines, selective serotonin reuptake inhibitors (SSRIs), and tricyclic antidepressants. Anxiety drugs are typically prescribed by a doctor or mental health professional. The drugs are usually taken orally, although some may be administered intravenously or intramuscularly. The dosage and duration of treatment vary depending on the individual's condition and response to the drug. Some of the major companies in the Anxiety Drugs market include Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca, and Johnson & Johnson. These companies produce a variety of anxiety drugs, including benzodiazepines, SSRIs, and tricyclic antidepressants. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.